The abstract is read at the publisher; the summary is JClub's.
LM103 autologous TIL monotherapy in 14 Chinese patients with refractory metastatic melanoma achieved an objective response rate of 35.7% and a median progression-free survival of 4.52 months.
- Why it matters: Standard therapy resistance leaves limited options for advanced melanoma, and early evidence is needed on both safety and immune mechanisms that predict clinical benefit.
- What they did: In a phase I study, patients received lymphodepleting chemotherapy, LM103 infusion (3.58–19.47×10¹⁰ cells), and high-dose interleukin-2, with baseline and pre-/post-infusion immune profiling and TCR repertoire tracking.
- The result: LM103 showed manageable safety with 100% myelosuppression and 35.7% objective responses; clinical benefit was linked to sustained in vivo clonal persistence, with >60% of infused TIL clones detectable in peripheral blood at 6 months.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.